AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02401256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.
Study NCT00292292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar Artificial Disc
Description: Insertion of the Kineflex Lumbar ArtificialDisc
Study NCT00292292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Charite Artificial Disc
Description: Insertion of the Charite
Study NCT01382589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation
Study NCT01382589 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: NB-UVB light therapy 3-times per week, for total of 72 treatments
Study NCT01264991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Description: The arthroscopic partial meniscectomy will be performed on an outpatient basis by experienced surgeons at a level of at least attending physicians or at the last year of residency. All arthroscopies will be performed in general anaesthesia combined with local anaesthesia. After general anaesthesia is induced, the knee will be examined for stability. Thereafter two standard portals on the lateral and medial side of the ligamentum patella will be created but no outflow cannula inserted. An arthroscope will be used with a pressure-controlled irrigation system. Tourniquet use will be according to surgeon preference. The strategy for the meniscectomy will be to preserve as much tissue as possible. A standard operation protocol will be used to document possible findings in cartilage, ligaments, synovium and the medial and lateral meniscus. Meniscus lesions and type of will be registered and changes in the articular cartilage will be classified according to the ICRS classification
Study NCT01264991 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham procedure
Description: The placebo procedure will be performed under the same conditions as above. The patient will be fully sedated in general anaesthesia. As above, the stability of the knee will be examined. Local anaesthetic will be applied as above and 2 skin incisions will be made at the same location and the same size as above. Then the knee will be manipulated as if a real arthroscopy were being done, the spillage of water and all the other equipment needed for an arthroscopy will be used and manipulated. No instruments will enter the portals for arthroscopy to avoid the possibility of osteochondral lesions and unwanted interventions by the surgeon.
Study NCT04384640 — intervention group
Intervention type: OTHER
Intervention: Change of posture after Intra Tympanic injection
Description: Seating position after Intra Tympanic injection
Study NCT00069095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130 mg/m^2
Description: Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.
Study NCT00069095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine 1000 mg/m^2
Description: Capecitabine was taken within 30 min after the end of breakfast and dinner.
Study NCT00069095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg
Description: Bevacizumab was administered in a 30 to 90 min infusion.
Study NCT00069095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for bevacizumab 7.5 mg/kg
Description: Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
Study NCT00069095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin 85 mg/m^2
Description: Oxaliplatin 85 mg/m\^2 was administered simultaneously with leucovorin in a 2 h infusion.
Study NCT00069095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin 200 mg/m^2
Description: Leucovorin was administered simultaneously with oxaliplatin 85 mg/m\^2 in a 2 h infusion.
Study NCT00069095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil 400 mg/m^2
Study NCT00069095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab 5 mg/kg
Description: Bevacizumab was administered in a 30 to 90 min infusion.
Study NCT00069095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for bevacizumab 5 mg/kg
Description: Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
Study NCT03073070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biotin labeled RBCs
Description: Autologous red blood cells are biotin labeled and transfused to the subjects. Survival of these red blood cells is tracked through examination of blood samples until no biotin-labeled red blood cells is detectable.
Study NCT03988777 — intervention group
Intervention type: DEVICE
Intervention: Preoperative localisation technique
Description: Impalpable breast lesions are preoperatively localised, either with hooked-wire (retrospective study) or Magseed (prospective study)
Study NCT02222987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbogrel
Study NCT02222987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbogrel
Study NCT02222987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT02222987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study NCT02645448 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resistance Exercise
Description: Control Session~Resistance exercise at different intensities (40%1RM or 80%1RM)~Duration of effect
Study NCT02093585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abacavir (600 mg QD)
Study NCT02093585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir (245 mg QD)
Study NCT04042662 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT03491163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Syndecan-1 concentration evaluation
Description: Blood sample will be taken and analysed using ELISA method.
Study NCT01165203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Vaccine GSK1437173A
Description: intramuscular injection
Study NCT06671899 — intervention group
Intervention type: OTHER
Intervention: Constraint-induced movement therapy (CIMT)
Description: Clinically implemented modified CIMT. Including the three main components; intensive and repetitive task-oriented training of the affected limb, constraint of the non-affected limb and behavioural strategies known as the Transfer Package. In this model the training is supervised by therapist from several professions and some training sessions is performed in group settings with other inpatients and outpatients undergoing primary rehabilitation at the clinic.
Study NCT02461511 — intervention group
Intervention type: OTHER
Intervention: Therapeutic Education
Description: participation in a therapeutic education program on diabetes
Study NCT02062411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT only
Description: Participants will learn 12 sessions including educational information about ADHD and skills in organization and plan, reducing distractibility, and adaptive thinking.
Study NCT02062411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT with booster sessions
Description: Participants are provided with the same CBT programme and additional 3 booster sessions which summarize and extend the 3 main topics of the CBT programme in order to improve the skills practice ability.
Study NCT04196296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Online psychoeducation about social anxiety, evidence-based treatments that target social anxiety, and treatment referral/resource information.
Study NCT01367587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Methylnaltrexone
Study NCT01165203 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscular injection
Study NCT01509586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product
Description: The PREP Group will be given a sample supply of a PREP product that is already on the market. It is unclear if it is safer than cigarettes, and that is why it is classified as a Potentially Reduced Exposure Product. It provides both nicotine and tobacco in the form of a pouch that can be thrown away after used. Unlike chewing tobacco, there is no need for spitting with this product. There are multiple flavors and participants will have his/her choice of preferred flavor. This group will be asked to sample the product and use it in several ways, but whether a participant uses the product or not is up him/her.
Study NCT01289392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Previously determinated airway pressure: used for two months unassociated with physical exercise and used for four months associated with physical exercise
Study NCT01289392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Appliance (OA)
Description: Anterior mandibular repositioner: used for two months unassociated with physical exercise and used for four months associated with physical exercise
Study NCT04196296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Online psychoeducation about social anxiety, evidence-based treatments that target social anxiety, and treatment referral/resource information.
Study NCT04196296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation
Description: Online exercises/activities regarding social anxiety (and treatment thereof) based in principles from Acceptance and Commitment Therapy (ACT) and Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET).
Study NCT02803879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiogoniometry
Study NCT01071551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-style intervention
Description: The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care.
Study NCT01071551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity only
Description: Children allocated to this group will attend 20 physical activity classes.
Study NCT01835548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT0102
Description: NT0102 (methylphenidate polistirex \[MPP\] extended release \[XR\] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.
Study NCT01835548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching ODT placebo was given once daily.
Study NCT03284697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Pulp Capping with Ca(OH)2
Description: Calcium hydroxide powder was mixed with saline and placed over the exposed pulp tissue. The cavities were then restored with resin modified GIC liner followed by composite restoration.
Study NCT03284697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Pulp Capping With MTA
Description: MTA was mixed using1:3 water/ powder ratio and applied to exposure site. Then cotton pellets soaked in normal saline was placed over MTA and cavity was sealed provisionally with IRM. After 24 hours, the patient was recalled and the cavity was restored with resin modified GIC liner followed by composite restoration.
Study NCT03419260 — intervention group
Intervention type: OTHER
Intervention: Clinically indicated EEG monitoring.
Description: Children enrolled in the study will be undergoing clinically indicated EEG monitoring. Some children will undergo clinically indicated electrographic seizure management.
Study NCT03736460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The mindfulness-based intervention adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of four 3h group sessions spread over 8 weeks. Each session consists of guided experiential mindfulness exercises (e.g. focus on the breath, body scan, breathing space, mindful movement, sitting meditation), sharing of experiences of these exercises, reflection in small groups, psycho-education (e.g. stress, depression, fear of cancer recurrence, self-care) and review of home practices.
Study NCT03736460 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: This intervention is based on the recommended levels of physical activity for adults aged 18 - 64 year from the World Health Organization. These recommendations are the same for women after a breast cancer treatment (Schmitz et al., 2010). Just as the mindfulness intervention this will consist of four 2h group sessions spread over 8 weeks. Each session will consist of psycho-education (e.g. basics of movement, advantages of physical activity, training-principles), endurance and resistance training, stretching, balance and relaxation exercises, sharing of experiences of these exercises and review of home practices.
Study NCT03428542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yin yoga
Description: Yin yoga 2 times per week for 5 weeks. Daily breathing assignments.
Study NCT03428542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: YOMI
Description: 30 minutes of psychoeducation combined with mindfulness practice followed by 60 minutes of Yin yoga allowing the psychological theme to be further explored, aided by verbal instructions of the yoga teacher. 2 times per week for 5 weeks.~Daily breathing assignments.
Study NCT04731324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYIL1 capsule
Description: NLRP3 inflammasome inhibitor
Study NCT00895050 — intervention group
Intervention type: OTHER
Intervention: Review of clinical records
Study NCT01740934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anatabloc Cream
Description: subject will apply active cream topically, twice per day according to instructions
Study NCT01740934 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: subject will apply placebo cream topically, twice per day according to instructions
Study NCT00735319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Bilirubinometer
Description: For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained
Study NCT02711527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupunture group A
Description: Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), Ligou蠡沟 (LR 5), Zhongdu 中都(LR6), Xiguan膝關 (LR 7), Ququan曲泉 (LR 8), Zhangmen章門(LR13), Qimen期門 (LR14).
Study NCT02711527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupunture group B
Description: Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), , Sanyinjiao 三陰交 (SP 6), Xuanzhong懸鐘 (GB 39), Shenmen 神門 (HT 7), Zusanli 足三里(ST 36), Baihui 百會(DU 20), Shenting神庭(DU24), Qihai 氣海(RN6), Guanyuan 關元(RN4). Teding Diancibo Pu (abbreviation: TDP) 特定電磁波譜 will be applied to Group B immediately after the needle insertion.
Study NCT04499209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG005
Description: XG005 Capsule
Study NCT04499209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of Naproxen and Pregabalin
Description: Naproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica
Study NCT04499209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Capsule
Study NCT02442297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2-specific T cells
Description: Dosing Schedule 1:~Cycle 1 A: 1x10\^7 cells~Cycle 2 A: 1x10\^7 cells~Cycle 3 A: 1x10\^7 cells~Dosing Schedule 2:~Cycle 1 A: 1x10\^7 cells~Cycle 2 B: 3x10\^7 cells~Cycle 3 B: 3x10\^7 cells~Dosing Schedule 3:~Cycle 1 A: 1x10\^7 cells~Cycle 2 B: 3x10\^7 cells~Cycle 3 C: 1x10\^8 cells~Subsequent cycles\*~\*Additional cycles may be administered at ≤ the final cell dose reached in cycle 3, provided that the subject continues to meet eligibility criteria and does not have confirmed progressive disease.
Study NCT01169038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levaquin; ethambutol; rifampin and azithromycin.
Description: Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~\*\*Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. \*\*We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway.
Study NCT01898845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Study NCT01016054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-8M4
Description: IV infusion
Study NCT01016054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: IV infusion
Study NCT01016054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: IV infusion
Study NCT01016054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV infusion
Study NCT01488448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% sodium chloride
Description: 4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
Study NCT01488448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: 4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
Study NCT02703285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound
Description: task of the participants in the study to determine the chest sound based on specific sounds: Vesicular - Diminished; Expiratory Wheeze; Bronchovesicular; pneumonia; pulmonary Oedema; Stridor; Agonal respiration
Study NCT03438643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: Blood samples (42mL) will be taken before and during treatment.
Study NCT03438643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: skin biopsy
Description: skin biopsy will be taken before and during treatment.
Study NCT01614262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring with treatment algorithm
Description: those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.
Study NCT01614262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring with treatment algorithm
Description: those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.
Study NCT04218994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flossing technique
Description: Subjects instructed on flossing technique
Study NCT02434809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic Implantation
Description: Calypso transponders
Study NCT02434809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cone-Beam CT-Guided
Study NCT02434809 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation treatments